XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1 variant
27 December 2022In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA has just carried out an... View Article
Naobios signs a Research License Agreement with Valneva on EB66® cell line
Naobios announced the signature of a Research License Agreement with Valneva to assess the EB66® cell line as cell substrate for the evaluation... View Article
OSE Immunotherapeutics receives €10 Million
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article